All In Biotech

Drug Trial Radar · NCT03583710

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Aug 20, 2018

Primary completion

Jan 1, 2029

Study completion Jan 1, 2029

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jul 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high risk of coming back (recurrence). Cortisol can cause the growth of adrenocortical tumor cells. Antihormone therapy, such as mitotane, may lessen the amount of cortisol made by the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether mitotane alone or mitotane with cisplatin and etoposide after surgery works better in treating patients with adrenocortical carcinoma.

Conditions

  • ENSAT Stage I Adrenal Cortex Carcinoma
  • ENSAT Stage II Adrenal Cortex Carcinoma
  • ENSAT Stage III Adrenal Cortex Carcinoma

Interventions

  • CisplatinDrug

    Given IV

  • EtoposideDrug

    Given IV

  • MitotaneDrug

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survival (RFS)Time frame: From the time of randomization up to 2 years
  2. Local recurrence of adrenocortical carcinoma (ACC)Time frame: Up to 6 months
  3. Distant recurrence of ACCTime frame: Up to 6 months

Locations

33 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Siteman Cancer Center at Washington University

    St Louis, Missouri · Active not recruiting

  • M D Anderson Cancer Center

    Houston, Texas · Recruiting

  • Institut de Cancérologie de l'Ouest (ICO)

    Angers, France · Active not recruiting

  • CHU Angers, Hôpital Larrey

    Angers, France · Recruiting

  • CHU Besançon, Hôpital Jean Minjoz

    Besançon, France · Recruiting

  • CHU Brest, Hôpital La Cavale Blanche

    Brest, France · Active not recruiting

  • Centre Georges François Leclerc

    Dijon, France · Recruiting

  • Lyon HCL

    Lyon, France · Recruiting

  • HCL Hôpital Louis Pradel

    Lyon, France · Not yet recruiting

  • Marseille Hôpital Nord

    Marseille, France · Recruiting

  • Marseille Hôpital de la Conception

    Marseille, France · Recruiting

  • CHU Nantes, Hôpital René et Guillaume Laënnec

    Nantes, France · Active not recruiting

  • CHU Nantes, Hôpital René et Guillaume Laënnec

    Nantes, France · Recruiting

  • Hôpital Cochin, AP-HP

    Paris, France · Recruiting

  • Hôpital Cochin, AP-HP

    Paris, France · Active not recruiting

  • Hôpital Cochin

    Paris, France · Recruiting

  • Hôpital COCHIN

    Paris, France · Active not recruiting

  • CHU Bordeaux - Hôpital Haut Lévèque

    Pessac, France · Recruiting

  • CHU Poitiers

    Poitiers, France · Recruiting

  • CHU Reims

    Reims, France · Recruiting

  • HUS, Hôpital Hautepierre

    Strasbourg, France · Not yet recruiting

  • Strasbourg HUS Hautepierre

    Strasbourg, France · Active not recruiting

  • CHU Toulouse, Hôpital Larrey

    Toulouse, France · Recruiting

  • CHU Toulouse, Hôpital Rangueil

    Toulouse, France · Active not recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • LMU Klinikum München

    Munich, Germany · Recruiting

  • Universitätsklinikum Würzburg

    Würzburg, Germany · Recruiting

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Gliwice, Poland · Active not recruiting

  • Sahlgrenska University Hospital

    Gothenburg, Sweden · Recruiting

  • Skånes Universitetssjukhus

    Lund, Sweden · Recruiting

  • Karolinska University Hospital

    Stockholm, Sweden · Recruiting

  • Akademiska Sjukhuset

    Uppsala, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.